Mucosal inflammation in idiopathic bronchiectasis: Cellular and molecular mechanisms

European Respiratory Journal

Volumn 31, Issue 2, 2008, Pages 396-406

  Fuschillo, S ^a   De Felice, A ^a   Balzano, G ^a  

^a IRCCS   (Italy)

Author keywords

Airway infection; Airway inflammation; Bronchiectasis

Indexed keywords

ASTHMA; ATYPICAL MYCOBACTERIOSIS; BACTERIAL COLONIZATION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; EOSINOPHIL; EPITHELIUM CELL; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HUMAN; LUNG INFECTION; LYMPHOCYTE FUNCTION; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; ANIMAL; BACTERIAL INFECTION; BRONCHITIS; CYTOLOGY; FEMALE; INFLAMMATION; INNATE IMMUNITY; MALE; METABOLISM; MOLECULAR BIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; SENSITIVITY AND SPECIFICITY;

CYTOKINE;

ANIMALS; BACTERIAL INFECTIONS; BRONCHIECTASIS; BRONCHITIS; CYTOKINES; FEMALE; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; MALE; MOLECULAR BIOLOGY; OXIDATIVE STRESS; RESPIRATORY MUCOSA; SENSITIVITY AND SPECIFICITY;

EID: 40649087414     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00069007     Document Type: Review

References (157)

1. Cole PJ. Bronchiectasis. In: Brewis RAL, Corin B, Geddes DM, Gibson GJ, eds. Respiratory Medicine. 2nd Edn. London, WB Saunders, 1995; pp. 1286-1316.
2. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383-1393.
3. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest 1999; 116: 1063-1074.
4. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
5. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004; 8: 691-702.
6. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128: 739-745.
7. Angrill J, Celis R, Arancibia F, et al. Bacterial colonization in patients with bronchiectasis: prevalence and comparison of diagnostic techniques. Am J Respir Crit Care Med 1999; 159: A559.
8. Pang JA, Cheng A, Chan HS, Poon D, French G. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am Rev Respir Dis 1988; 139: 14-17.
9. Tsang KW, Chan KN, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117: 420-426.
10. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158: 723-727.
11. Cole PJ. Inflammation: a two edged-sword - the model of bronchiectasis. Eur J Respir Dis 1986; 69: Suppl. 147, 6-15.
12. Bonfield TL, Panuska JR, Konstan M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
13. Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM. TNF-α, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 11-19.
14. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-1632.
15. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
16. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20: 63-70.
17. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
18. Linden M, Rasmussen JB, Piitulainen E, et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148: 1226-1232.
19. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell profiles of asthmatic and non-asthmatic subjects. Am Rev Respir Dis 1987; 136: 379-383.
20. Wilson CB, Jones PW, O'Leary CJ, et al. Systemic marker of inflammation in stable bronchiectasis. Eur Respir J 1998; 12: 820-824.
21. Feldmann M, Maini RN. Anti-TNF a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
22. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33.
23. Wilson R, Dowlin RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996; 9: 1523-1530.
24. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester Kirchner H, Berger JM. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 2002; 165: 1176-1181.
25. Aldallal N, McNaughton EE, Manzel LJ, et al. Inflammatory response in airway epithelial cells isolated from patients with cystic fribrosis. Am J Respir Crit Care Med 2002; 166: 1248-1256.
26. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003; 4: 8.
27. King PT, Hutchinson PE, Johnson PD, Holmes PW, Freezer NJ, Holdsworth SR. Adaptive immunity to non typeable Haemophilus influenzae. Am J Respir Crit Care Med 2003; 167: 587-592.
28. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171: 1209-1223.
29. Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opinion Infect Dis 2003; 16: 135-143.
30. Travassos LH, Carneiro LAM, Girardin SE, et al. Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J Biol Chem 2005; 280: 36714-36718.
31. Lapa e Silva JR, Guerreiro D, Noble B, Poulter LW, Cole PJ. Immunopathology of experimental bronchiectasis. Am J Respir Cell Mol Biol 1989; 1: 297-304.
32. Adler KB, Fischer BM, Wright DT, Cohn LA, Becker S. Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation. Ann NY Acad Sci 1994; 725: 128-145.
33. Cheung DOY, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun 2000; 68: 4585-4592.
34. Lu W, Hisatsune A, Koga T, et al. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J Immunol 2006; 176: 3890-3894.
35. Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145: 1349-1357.
36. Jensen ET, Kharazmi A, Lam K, Costerton JW, Høiby N. Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilm. Infect Immun 1990; 58: 2383-2385.
37. Anwar H, Strap JL, Costerton JW. Susceptibility of biofilm cells of Pseudomonas aeruginosa to bactericidal actions of whole blood and serum. FEMS Microbiol Lett 1992; 92: 235-242.
38. Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995; 155: 2029-2038.
39. Pedersen SS. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl 1992; 28: 1-79.
40. Simpson JA, Smith SE, Dean RT. Scavenging by alginate of free radicals released by macrophages. Free Radical Biol Med 1989; 6: 347-353.
41. Learn DB, Brestel EP, Seetharama S. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun 1987; 55: 1813-818.
42. Høiby N. Antibiotic therapy for chronic infection of Pseudomonas aeruginosa in the lung. Annu Rev Med 1993; 44: 1-10.
43. Calum H, Moser C, Jensen PØ, Shirai R, Høiby N. Cytokine and surface receptor diversity of NK cells in resistant C3H/HeN and susceptible BALB/c mice with chronic Pseudomonas aeruginosa lung infection. APMIS 2003; 111: 891-897.
44. Somersalo K, Carpén O, Saksela E. Stimulated natural killer cells secrete factors with chemotactic activity, including NAP-1/IL-8, which support VLA-4 and VLA-5 mediated migration of lymphocytes. Eur J Immunol 1994; 24: 2957-2965.
45. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
46. Vankayalapati R, Wizel B, Samten B, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J Infect Dis 2001; 183: 478-484.
47. Greenwell-Wild T, Vázquez N, Sim D, et al. Mycobacterium avium infection and modulation of human macrophage gene expression. J Immunology 2002; 169: 6286-6297.
48. Fujita J, Ohtsuki Y, Suemitsu I, et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J 1999; 13: 535-540.
49. Wittram C, Weisbrod GL. Mycobacterium avium complex lung disease in immunocompetent patients: radiography-CT correlation. British J Radiol 2002; 75: 340-344.
50. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-868.
51. Kubo K, Yamazaki Y, Hachiya T. Mycobacterium avium-intracellulare pulmonary infection in patients without known predisposing lung disease. Lung 1998; 176: 381-391.
52. Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology 1993; 187: 23-26.
53. Tanaka E, Amitani R, Niimi A, Suzuki K, Murayama T, Kuze F. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155: 2041-2046.
54. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minóprio P. Role of γ-interferon and tumor necrosis factor α during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun 1994; 62: 3962-3971.
55. + lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route. Infect Immun 2005; 73: 2621-2627.
56. Bermudez LE, Kolonoski P, Young LS. Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model. J Leukoc Biol 1990; 47: 135-141.
57. Bermudez LE, Young LS. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 1991; 146: 265-270.
58. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
59. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J Exp Med 1993; 178: 2243-2247.
60. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428-5435.
61. Murphey ED, Herndon DN, Sherwood ER. γ-Interferon does not enhance clearance of Pseudomonas aeruginosa but does amplify a proinflammatory response in a murine model of postseptic immunosuppression. Infect Immun 2004; 72: 6892-6901.
62. Tsukaguchi K, Yoneda T, Okamura H, et al. Defective T cell function for inhibition of growth of Mycobacterium avium-intracellulare complex (MAC) in patients with MAC disease: restoration by cytokines. J Infect Dis 2000; 182: 1664-1671.
63. Frucht DM, Holland SM. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol 1996; 157: 411-416.
64. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101: 2364-2369.
65. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB Jr. Haemophilus influenzae forms biofilms on airway epithelia. Am J Respir Crit Care Med 2006; 174: 213-220.
66. Frick AG, Joseph TD, Pang L, Rabe AM, St Geme JW 3rd, Look DC. Haemophilus influenzae stimulates ICAM-1 expression on respiratory epithelial cells. J Immunol 2000; 164: 4185-4196.
67. Wang X, Moser C, Louboutin JP, et al. Toll like receptor 4 mediates innate immune response to Haemophilus influenzae infection in mouse lung. J Immunol 2002; 168: 810-815.
68. Smith A. Pathogenesis of bacteria bronchitis in cystic fibrosis. Pediatr Infect Dis J 1997; 16: 91-95.
69. Witko-Sarsat V, Rieu P, Descamps-Latscha P, Lesaure P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 80: 617-653.
70. Liu Y, Shaw SK, Ma S, Yang L, Luscinskas FW, Parkos CA. Regulation of leukocyte transmigration: cell surface interactions and signaling events. J Immunol 2004; 172: 7-13.
71. Ben-Beruch A, Michiel DF, Oppenhein JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995; 270: 11703-11706.
72. Eller J, Lapa e Silva JR, Poulter LW, Lode H, Cole PJ. Cells and cytokines in chronic bronchial infection. Ann NY Acad Sci 1994; 725: 331-345.
73. 2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002; 121: 81-87.
74. Zheng L, Shum H, Tipoe GL, et al. Macrophages, neutrophils and tumor necrosis factor-α expression in bronchiectatic airways in vivo. Respir Med 2001; 95: 792-798.
75. Gaga M, Bentley AM, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685-691.
76. Schleimer RP, Benenati SV, Friedman B, Bochner BS. Do cytokines play a role in leukocyte recruitment and activation in the lung? Am Rev Respir Dis 1991; 143: 1169-1174.
77. Khair OA, Davies RJ, Devalia JL. Bacterial-induced release of inflammatory mediators by bronchial epithelial cells. Eur Respir J 1996; 9: 1913-1922.
78. Reaves TA, Chin AC, Parkos CA. Neutrophil transepithelial migration: role of toll-like receptors in mucosal inflammation. Mem Inst Oswaldo Cruz 2005; 100: Suppl. 1, 191-198.
79. Hogg JC. Leukocyte traffic in the lung. Ann Rev Physiol 1995; 57: 97-114.
80. Adams DH, Sham S. Leukocyte endothelial inter-reactions in regulation of leukocytes and migration. Lancet 1994; 343: 831-835.
81. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
82. Humlicek AL, Pang LY, Look DC. Modulation of airway inflammation and bacterial clearance by epithelial cell ICAM-1. Am J Physiol Lung Cell Mol Physiol 2004; 287: L598-L607.
83. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379-387.
84. Carlos T, Kovach N, Schwarz B, et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocytes adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991; 77: 2266-2271.
85. Zheng L, Tipoe G, Lam WK, et al. Up-regulation of circulating adhesion molecules in bronchiectasis. Eur Respir J 2000; 16: 691-696.
86. Parkos CA, Colgan SP, Liang TW, et al. CD47 mediates post-adhesive events required for neutrophil migration across polarized intestinal epithelia. J Cell Biol 1996; 132: 437-450.
87. Dustin ML, Rothlein R, Bhan AF, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ: tissue distribution, biochemistry and function of a nature adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
88. Detmers PA, Lo SK, Olsen-Egbert E, Walz A, Baggioloini M, Cohn ZA. Neutrophil-activating protein-1/interleukin-8 stimulates the binding activity of leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990; 171: 1155-1162.
89. Jatakanon A, Lalloo UG, Lim S, Chung KF, Barnes PJ. Increased neutrophils and cytokines, TNF-α and IL-8 in induced sputum of non-asthmatic patients with chronic dry cough. Thorax 1999; 54: 234-237.
90. Hayashi F, Means TK, Leuster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102: 2660-2669.
91. Akira S. Toll-like receptors and innate immunity. Adv Immunol 2001; 78: 1-56.
92. Simpson JL, Grissell TV, Gibson PG. Innate immune activation in bronchiectasis. Eur Respir J 2004; 24: Suppl. 48, 210S.
93. Mikami M, Llewellyn-Jones CG, Bayley D, Hill SL, Stockley RA. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998; 157: 723-728.
94. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease. Molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
95. Beeh KM, Kornmann O, Buhl R, Gulpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
96. Fan J, Malik AB. Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat Med 2003; 9: 315-321.
97. Bédard M, McClure CD, Schiller NL, Francoeur C, Cantin A, Denis M. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol 1993; 9: 455-462.
98. Vandivier RW, Fadok VA, Hoffman PR, et al. Elastase mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-670.
99. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999; 276: L835-L843.
100. O'Connor CM, FitzGerald MX. Matrix metalloproteinases and lung disease. Thorax 1994; 49: 602-609.
101. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-735.
102. Corbel M, Lagente V, Boichot E. Pulmonary inflammation and tissue remodeling: role of metalloproteinases. Eur Respir Rev 2000; 10: 260-263.
103. Sepper R, Kontinnen YT, Ding Y, Takagi M, Sorsa T. Human neutrophil collagenase (MMP-8) identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 1995; 107: 1641-1647.
104. Sepper R, Kontinnen YT, Sorsa T, Koshi H. Gelationolytic and type IV collagenolytic activity in bronchiectasis. Chest 1994; 106: 1129-1133.
105. Zheng L, Lam WK, Tipoe GL, et al. Overexpression of matrix metalloproteinases-8 and -9 in bronchiectasis airways in vivo. Eur Respir J 2002; 20: 170-176.
106. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160: S49-S52.
107. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-S117.
108. Shun KY, Chan SCH, Ip MSM. Neutrophil-mediated degradation of lung proteoglycans. Stimulation by tumor necrosis factor-α in sputum of patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1925-1931.
109. Lloberes P, Monserrat E, Monserrat JM, Picado C. Sputum sol phase proteins and elastase activity in patients with clinically stable bronchiectasis. Thorax 1992; 47: 88-92.
110. Stockley RA. The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 1994;1, 50: S109-S113.
111. Sepper R, Kouttinen YT, Ingman T, Sorsa T. Presence, activities, and molecular forms of cathepsin G, elastase, alpha 1-antitrypsin, and alpha 1-antichymotrypsin in bronchiectasis. J Clin Immunol 1195; 15: 27-34.
112. Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase on bacterial proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26-32.
113. Zheng L, Tipoe G, Lam W-K, et al. Endothelin-1 in stable bronchiectasis. Eur Respir J 2000; 16: 146-149.
114. Punturieri A, Filippov S, Allen E, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000; 192: 789-799.
115. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: role of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002; 283: L867-L873.
116. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001; 276: 1071-1077.
117. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure to phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-2216.
118. Brouckaert G, Kalai M, Krysko DV, et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2004; 15: 1089-1100.
119. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine specific clearance of apoptotic cells. Nature 2000; 405: 85-90.
120. Aprikan AAG, Liles WC, Dale DC. Emerging role of apoptosis in the pathogenesis of severe neutropenia. Curr Opin Hematol 2000; 7: 131-132.
121. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999; 160: S5-S11.
122. Silva JR, Jones J, Cole PJ, Poulter LW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44: 668-673.
123. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171: 1209-1223.
124. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol 2000; 121: 173-178.
125. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med 1995; 333: 431-440.
126. Boyton RJ, Smith J, Ward R, et al. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006; 173: 327-333.
127. Ip M, Lauder IJ, Wong WY, Lam WK, So SY. Multivariate analysis of factors affecting pulmonary function in bronchiectasis. Respiration 1993; 60: 45-50.
128. Kroegel C, Schuler M, Forster M, Braun R, Grahmann PR. Evidence for eosinophil activation in bronchiectasis, unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy between blood eosinophil counts and serum eosinophil cationic protein levels. Thorax 1998; 53: 498-500.
129. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
130. Ferkol TW, Look DC. Chinks in the armor of the airway: Pseudomonas infection in the cystic fibrosis lung. Am J Respir Cell Mol Biol 2001; 25: 11-13.
131. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 2001; 13: 89-95.
132. Devalia JL, Davies RJ. Airway epithelial cells and mediators of inflammation. Respir Med 1993; 87: 405-408.
133. Devalia JL, Campbell AM, Sapsford RJ. Effect of nitrogen dioxide on the synthesis of inflammatory cytokines expressed by human bronchial epithelial cells in vitro. Am J Respir Cell Mol Biol 1993; 9: 271-278.
134. Humlicek AL, Pang L, Look DC. Modulation of airway inflammation and bacterial clearance by epithelial cell ICAM-1. Am J Physiol Lung Cell Mol Physiol 2004; 287: L598-L607.
135. Look DC, Rapp SR, Keller BT, Holtzman MJ. Selective induction of intercellular adhesion molecule-1 by interferon-γ in human airway epithelial cells. Am J Physiol 1992; 263: L79-L87.
136. Qin L, Quinlan WM, Doyle NA, et al. The role of CD11/CD18 and ICAM-1 in acute Pseudomonas aeruginosainduced pneumonia in mice. J Immunol 1996; 157: 5016-5021.
137. Schnitzler N, Haase G, Podbielski A, Lütticken R, Schweizer KG. A co-stimulatory signal through ICAM-β2 integrin-binding potentiates neutrophil phagocytosis. Nat Med 1999; 5: 231-235.
138. Schleimer RR. Glucocorticoids suppress inflammatory but spare innate immune responses in airway epithelium. Proc Amer Thorac Soc 2004; 1: 222-230.
139. Kirschning CJ, Schumann RR. TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr Opin Microbiol Immunol 2002; 270: 121-144.
140. Loukides S, Horvath I, Wodehouse T, Cole PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. AmJ Respir Crit CareMed 1998; 158: 991-994.
141. Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax 1998; 53: 867-870.
142. Repin JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
143. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
144. Tonnel AB, Wallaert B. Oxidants and bronchial inflammation. Eur Respir J 1990; 3: 987-988.
145. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
146. Biagioli MC, Kaul P, Singh I, Turner RB. The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. Free Radic Biol Med 1999; 26: 454-462.
147. Rahman I, Morrison D, Donaldson K. Systemic oxidative stress in asthma, COPD and smokers. Am J Respir Crit Care Med 1996; 154: 1055-1060.
148. Barnes PJ. Reactive oxygen species and airway inflammation. Free Radic Biol Med 1990; 9: 235-243.
149. 2 release by neutrophil leukocytes. J Immunol 1995; 154: 1385-1389.
150. Hensen PM, Johnston RB. Tissue injury in inflammation. J Clin Invest 1987; 79: 669-674.
151. Wood LG, Garg ML, Simpson JL, et al. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005; 171: 426-430.
152. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220.
153. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177.
154. Choi AMK, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Crit Care Med 1996; 15: 9-19.
155. Tenhumen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-755.
156. Abraham NG, Drummond GS, Lutton JD, Kappas A. The biological significance and physiological role of heme oxygenase. Cell Physiol Biochem 1996; 6: 129-168.
157. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nature Med 1996; 2: 87-90.